Funda Meric, MD
Surgery · Houston, TXNPI 1306932074
Payments from drug & device makers
Across 847 payments — averaging $24,308 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Company LTD$4.3M
- AstraZeneca$3.7M
- Daiichi Sankyo Inc.$3M
- Novartis$1.8M
- Taiho Oncology, Inc.$1.3M
- Pfizer$1.1M
- plus $5.3M from 29 others
Across 5 payments — averaging $981.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4K
- F. Hoffmann-la Roche AG$336
- Amgen$99
What the payments were for
- Consulting fees$115,07081%
- Speaking & faculty fees$5,2674%
- Travel & lodging$16,61412%
- Food & beverage$4,3383%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Company LTD | 65 | $4,324,622 |
| AstraZeneca | 43 | $3,695,694 |
| Daiichi Sankyo Inc. | 423 | $2,995,498 |
| Novartis | 25 | $1,810,480 |
| Taiho Oncology, Inc. | 54 | $1,318,280 |
| Pfizer(2 entities) | 34 | $1,103,570 |
| Merck | 6 | $912,157 |
| Sanofi US Services Inc. | 14 | $619,923 |
| Jazz Pharmaceuticals Inc. | 6 | $603,438 |
| Eli Lilly | 5 | $476,132 |
| Seagen Inc. | 43 | $447,888 |
| Astrazeneca UK Limited | 31 | $405,259 |
| Puma Biotechnology, Inc. | 10 | $343,664 |
| Genentech, Inc. | 19 | $339,604 |
| AbbVie | 7 | $281,968 |
| Amgen | 2 | $228,360 |
| GSK | 15 | $226,533 |
| Merck Healthcare Kgaa | 1 | $153,098 |
| EMD Serono, Inc. | 3 | $122,884 |
| Theratechnologies Inc. | 10 | $106,336 |
| F. Hoffmann-la Roche AG | 8 | $28,155 |
| Merck Kgaa | 1 | $13,654 |
| Boehringer Ingelheim International GmbH | 1 | $6,090 |
| Incyte Corporation | 5 | $6,000 |
| Karyopharm Therapeutics Inc. | 1 | $5,000 |
| Sanofi | 4 | $4,580 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,828 |
| Eisai Inc. | 1 | $3,594 |
| Chugai Pharmaceutical Co., Ltd. | 2 | $1,201 |
| Tempus AI, Inc | 1 | $1,000 |
| Lexicon Pharmaceuticals, Inc. | 2 | $143 |
| Stemline Therapeutics Inc. | 1 | $124 |
| Blueprint Medicines Corporation | 1 | $98 |
| Exelixis Inc. | 1 | $74 |
| Gilead | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,588,948 in reported general payments places this provider in the 95th percentile of 1,830 surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgery in Houston
- Isidoro WienerHouston$850K
- Mark HobeikaHouston$462K
- Joseph CoselliHouston$382K
- James SuliburkHouston$161K
- Richard KnightHouston$147K
- Michael HarkinsTomball$2.7M
- Lloyd StegemannCorpus Christi$1.9M
- Douglas StoddardAustin$1.4M
- Erik WilsonBellaire$1.2M
- Thomas SerenaShenandoah$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.